CAVALRY BIOSCIENCES INC
San Francisco, CA · Biotech · Private
Growth Plate IGF1 (GP-IGF1) fusion protein—a biotherapeutic combining IGF1 with an anti-matrilin-3 antibody arm for targeted localization to growth plates in Turner syndrome.
- Grants
- $549K
- 2 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 13
- 0 granted · 13 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Growth plate-targeted IGF1 to treat Turner Syndrome | $274,596 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Growth plate-targeted IGF1 to treat Turner Syndrome | $274,596 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3256 | Antiger Therapeutics Inc. | — | — |
| 3257 | ADVANCED RNA TECHNOLOGIES, LLC | — | — |
| 3258 | RESEARCH AND DIAGNOSTIC SYSTEMS, INC. | — | — |
| 3259 | CAVALRY BIOSCIENCES INC | — | — |
| 3260 | NeuroFx, Inc. | — | — |
| 3261 | Tessa Therapeutics | — | — |
| 3262 | Oblenio Bio | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- IGF-1-RELATED Compositions And Uses Of The Sameapplication
- Compositions And Methods For Treating Meibomian Gland Dysfunctionapplication
- Treating Ocular Conditions By Administering An IGF-1application
- ITGA7 Targeting Agents And Their Usesapplication
- IGF-1-RELATED Compositions And Uses Of The Sameapplication
- IGF-1-RELATED Compositions And Uses Of The Sameapplication
- IGF-1-RELEATED Compositions And Uses Of The Sameapplication
- IGF-1-RELEATED Compositions And Uses Of The Sameapplication
- Compositions And Methods For Treating Meibomain Gland Dysfunctionapplication
- Compositions For Targeting Muscle Cells And Uses Thereofapplication
- Compositions And Methods For Treating Meibomian Gland Dysfunctionapplication
- IGF-1-RELATED Compositions And Uses Of The Sameapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.